Using modafinil to treat fatigue in parkinson disease: A double-blind, placebo-controlled pilot study

Clinical Neuropharmacology

Volumn 32, Issue 6, 2009, Pages 305-310

  Lou, Jau Shin ^a   Dimitrova, Diana M ^a   Park, Byung S ^b   Johnson, Sarah C ^a   Eaton, Ryan ^a   Arnold, Grace ^a   Nutt, John G ^a  

^a OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

^b OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

Author keywords

Fatigue; Parkinson disease parkinsonism; Quality of life

Indexed keywords

MODAFINIL; PLACEBO;

ADULT; AGED; AMNESIA; ARTICLE; BALANCE IMPAIRMENT; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; EPWORTH SLEEPINESS SCALE; FATIGUE; FEMALE; FINGER; FLATULENCE; HEMATURIA; HUMAN; MALE; MOTOR PERFORMANCE; PARKINSON DISEASE; POLLAKISURIA; PRIORITY JOURNAL; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; RATING SCALE; SIDE EFFECT; WAKEFULNESS;

AGED; AGED, 80 AND OVER; BENZHYDRYL COMPOUNDS; CENTRAL NERVOUS SYSTEM STIMULANTS; DEPRESSION; DOUBLE-BLIND METHOD; FATIGUE; FEMALE; FINGERS; HUMANS; MALE; MIDDLE AGED; NEUROPSYCHOLOGICAL TESTS; PARKINSON DISEASE; PILOT PROJECTS; PSYCHOMOTOR PERFORMANCE; QUALITY OF LIFE; SEVERITY OF ILLNESS INDEX; SLEEP DISORDERS; TIME PERCEPTION; TREATMENT OUTCOME;

EID: 74249114595     PISSN: 03625664     EISSN: None     Source Type: Journal    
DOI: 10.1097/WNF.0b013e3181aa916a     Document Type: Article

References (17)

1. Friedman JH, Brown RG, Comella C, et al. Fatigue in Parkinson's disease: a review. Mov Disord 2007;22(3):297-308.
2. Shulman LM, Taback RL, Rabinstein AA, et al. Non-recognition of depression and other non-motor symptoms in Parkinson's disease. Parkinsonism Relat Disord 2002;8:193-197.
3. Garber CE, Friedman JH. Effects of fatigue on physical activity and function in patients with Parkinson's disease. Neurology 2003;60: 1119-1124.
4. Herlofson K, Larsen JP. The influence of fatigue on health-related quality of life in patients with Parkinson's disease. Acta Neurol Scand 2003;107:1-6.
5. Lou JS, Kearns G, Benice T, et al. Levodopa improves physical fatigue in Parkinson's diseaseVa double-blind, placebo-controlled crossover study. Mov Disord 2003;18:1108-1114.
6. Lou JS, Kearns G, Oken B, et al. Exacerbated physical fatigue and mental fatigue in Parkinson's disease. Mov Disord 2001;16:190-196.
7. US Modafinil in Narcolepsy Multicenter Study Group. Randomized trial of modafinil: a treatment for the excessive daytime somnolence of narcolepsy. Neurology 2000;54:1166-1175.
8. Scammell TE, Estabrook IV, McCarthy MT, et al. Hypothalamic arousal regions are activated during modafinil-induced wakefulness. J Neurosci 2000;20:8620-8628.
9. Ondo WG, Fayle R, Atassi F, et al. Modafinil for daytime somnolence in Parkinson's disease: double blind, placebo controlled parallel trial. J Neurol Neurosurg Psychiatry 2005;76:1636-1639.
10. Adler CH, Caviness JN, Hentz JG, et al. Randomized trial of modafinil for treating subjective daytime sleepiness in patients with Parkinson's disease. Mov Disord 2003;18:287-293.
11. Smets EMA, Grassen B, Bonke B, et al. The Multidimensional Fatigue Inventory (MFI) psychometric qualities of an instrument to assess fatigue. J Psychosom Res 1995;39:315-325.
12. Hogl B, Saletu M, Brandauer E, et al. Modafinil for the treatment of daytime sleepiness in Parkinson's disease: a double-blind, randomized, crossover, placebo-controlled polygraphic trial. Sleep 2002;25:905-909.
13. Nieves AV, Lang AE. Treatment of excessive daytime sleepiness in patients with Parkinson's disease with modafinil. Clin Neuropharmacol 2002;25:111-114.
14. Ferraro L, Tanganelli S, O'Connor WT, et al. The vigilance promoting drug modafinil increases dopamine release in the rat nucleus accumbens via the involvement of a local GABAergic mechanism. Eur J Pharmacol 1996;306:33-39.
15. De Saint Hilaire Z, Orosco M, Rouch C, et al. Variations in extracellular monoamines in the prefrontal cortex and medial hypothalamus after modafinil administration: a microdialysis study in rats. Neuroreport 2001;12:3533-3537.
16. Jenner P, Zeng BY, Smith LA, et al. Antiparkinsonian and neuroprotective effects of modafinil in the MPTP-treated common marmoset. Exp Brain Res 2000;133:178-188.
17. Madras BK, Xie Z, Lin Z, et al. Modafinil occupies dopamine and norepinephrine transporters in vivo and modulates the transporters and trace amine activity in vitro. J Pharmacol Exp Ther 2006;319:561-569.